Tiziana Life Sciences Ltd (TLSA)
Automate Your Wheel Strategy on TLSA
With Tiblio's Option Bot, you can configure your own wheel strategy including TLSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLSA
- Rev/Share 0.0
- Book/Share 0.0545
- PB 25.8584
- Debt/Equity 0.0446
- CurrentRatio 1.122
- ROIC -3.1908
- MktCap 157162830.0
- FreeCF/Share -0.1546
- PFCF -10.0116
- PE -8.0918
- Debt/Assets 0.0203
- DivYield 0
- ROE -1.4092
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows
Published: May 15, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA)' investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a 78-year-old patient with moderate Alzheimer's disease (AD), a newly published study has shown. The study, published in the Journal of Clinical Nuclear Medicine, was led by Dr Tarun Singhal and Dr Howard Weiner of Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system.
Read More
Tiziana Life Sciences Announces Purchase of Shares by Chairman
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr.
Read More
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab
Published: May 09, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer's disease showed a marked reduction in brain inflammation after three months of treatment with its lead drug candidate, intranasal foralumab, under an expanded access program. A PET scan revealed a significant decrease in microglial activation—an indicator of neuroinflammation linked to Alzheimer's progression—according to data presented by Dr Howard Weiner at the 2025 AD/PD Conference in Vienna.
Read More
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer's disease (AD) who was treated for three months with intranasal foralumab under an expanded access program. The microglial TSPO PET scan revealed a significant decrease in microglia activation, a key indicator of neuroinflammation associated with Alzheimer's disease progression.
Read More
Tiziana shares surge 21% on promising multiple sclerosis data
Published: May 06, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares jumped 21% in early trading Tuesday after the company reported positive early-stage data for its experimental multiple sclerosis treatment, nasal foralumab. The open-label study involved 10 patients with non-active secondary progressive MS, a form of the disease where disability progresses despite the absence of relapses and few treatment options exist.
Read More
Tiziana reports encouraging results for nasal MS drug in early study
Published: May 06, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday that its experimental multiple sclerosis therapy, nasal foralumab, showed positive results in an early-stage study, with patients experiencing stabilised disease progression and reduced signs of brain inflammation. The open-label study followed 10 patients with non-active secondary progressive multiple sclerosis, or na-SPMS, a difficult-to-treat form of the disease in which disability worsens even in the absence of relapses.
Read More
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients. All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores.
Read More
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins
Published: April 02, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Johns Hopkins University has begun dosing patients in its Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This marks the third clinical site for the trial, alongside Brigham and Women's Hospital and Yale Medical Center.
Read More
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing of new patients at Yale MS Center which is participating in our multicenter Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
Read More
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Traumatic brain injury is a leading cause of death and disability Currently, there is no treatment to prevent the long-term effects of traumatic brain injury Findings could translate into treating intracerebral hemorrhage or stroke NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the publication of a landmark study in Nature Neuroscience demonstrating that nasal administration of Tiziana's anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery.
Read More
Tiziana Life Sciences nearing completion of long COVID study on foralumab
Published: February 25, 2025 by: Proactive Investors
Sentiment: Neutral
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it expects to complete its preclinical study evaluating its nasal anti-CD3 foralumab as a potential treatment for long COVID in the second quarter of 2025. The company said the study aims to validate foralumab's ability to mitigate persistent brain inflammation, a key driver of the neurological and psychiatric symptoms associated with long COVID.
Read More
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nasal anti-CD3 (foralumab) preclinical study is nearing completion, and that foralumab could offer a novel and effective treatment for long COVID.
Read More
Tiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnership
Published: February 21, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a new agreement with Renaissance Lakewood LLC to advance the development of its lead therapeutic candidate intranasal foralumab. The partnership will focus on optimizing the formulation and scaling up production of the investigational therapy, which is being developed for neurodegenerative and inflammatory diseases.
Read More
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced a product development services agreement with Renaissance Lakewood LLC (“Renaissance”), a leading Contract Development and Manufacturing Organization (CDMO) focused on nasal drug delivery. This collaboration aims to optimize the current formulation and develop a comprehensive plan for the scale-up of foralumab in a nasal device. Intranasal foralumab is currently under development for treating neurodegenerative and inflammatory diseases or conditions.
Read More
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) for patients with non-active secondary progressive multiple sclerosis (na-SPMS) who do not qualify for the ongoing Phase 2a study (NCT06292923).
Read More
Tiziana Life Sciences says foralumab shows promise in Alzheimer's treatment
Published: February 11, 2025 by: Proactive Investors
Sentiment: Positive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational drug, intranasal foralumab, is gaining attention for its potential to address Alzheimer's disease, a condition with limited treatment options. The company's expanded access program for moderate Alzheimer's has allowed the first patient to receive the therapy, offering hope for those battling the disease.
Read More
About Tiziana Life Sciences Ltd (TLSA)
- IPO Date 2018-11-20
- Website https://www.tizianalifesciences.com
- Industry Biotechnology
- CEO Dr. Ivor R. Elrifi Ph.D.
- Employees 9